-+ 0.00%
-+ 0.00%
-+ 0.00%

Kamada signs three-year USD 50 million plasma supply agreement with biopharmaceutical company

PUBT·07/20/2026 11:06:00
Listen to the news
Kamada signs three-year USD 50 million plasma supply agreement with biopharmaceutical company
  • Kamada signed a three-year plasma supply agreement valued at about USD 50 million with a major plasma-derived therapies company.
  • Revenue is expected to be recorded starting in Q4 2026, with sales over the three-year term.
  • Plasma will be sourced from its Texas collection centers, supporting its vertical integration and plasma sales ramp-up strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200700PRIMZONEFULLFEED9764477) on July 20, 2026, and is solely responsible for the information contained therein.